Chase leads marketing at RIS Rx, where he advances the company’s leadership in gross-to-net (GTN) revenue protection. His work helps pharmaceutical manufacturers navigate market access complexity and protect GTN performance. Chase holds an AB from Harvard University.
March 18, 2026
"*" indicates required fields
RIS Rx offers real-time GTN Revenue Protection to the world's leading pharmaceutical manufacturers, ensuring that every dollar allocated for affordability reaches the right patient at the right time.
RIS Rx is pioneering real-time GTN Revenue Protection for the world's leading pharmaceutical manufacturers, ensuring that every dollar allocated for affordability reaches the right patients at the right time.